AI Article Synopsis
- A study was conducted using glycoprotein G-based assays from Focus and Kalon to test 118 patients with confirmed genital herpes, comparing their effectiveness.
- The Focus assay showed higher sensitivity (86%) for first HSV-2 episodes compared to Kalon's sensitivity of 52%, but both tests were equally sensitive (100%) for recurrent episodes.
- Seroconversion times varied significantly: Kalon took a median of 120 days, Focus took 21 days, and Western blotting took 68 days, while specificity was 100% for Kalon and 93% for Focus.
Article Abstract
Glycoprotein G-based herpes simplex virus type 2 (HSV-2) enzyme-linked immunosorbent assays from Focus and Kalon were performed with specimens from 118 patients with culture-documented genital herpes episodes, and their results were compared. Sensitivity was 52% by Kalon and 86% by Focus for first HSV-2 episodes and 100% (for each of the two tests) for recurrent HSV-2. Median times to seroconversion were 120 days by the Kalon assay, 21 days by the Focus assay, and 68 days by Western blotting assay. Values for specificity were 100% (Kalon) and 93% (Focus).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC262548 | PMC |
| http://dx.doi.org/10.1128/JCM.41.11.5212-5214.2003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Seroprevalence of Herpes Simplex Virus type-2 (HSV-2) among pregnant women who participated in a national HIV surveillance activity in Haiti.
BMC Infect Dis
August 2017
Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA, 30329, USA.
Background: Herpes simplex virus type 2 (HSV-2), one the most common causes of genital ulcers, appears to increase both the risk of HIV acquisition and HIV transmission. HSV-2/HIV co-infection among pregnant women may increase the risk of perinatal transmission of HIV. This study describes rates of HSV-2 among pregnant women in Haiti and HSV-2 test performance in this population.
View Article and Find Full Text PDFEvaluation of Herpes Simplex Virus Type 2 Serological Tests for Use With Dried Blood Spots in Kenya.
Sex Transm Dis
February 2017
From the *Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; †National HIV Reference Laboratory, Ministry of Health, Nairobi, Kenya; ‡Pacific Institute for Research and Evaluation; and §Department of Maternal and Child Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.
We evaluated 2 assays to detect antibodies to herpes simplex virus type 2 in dried blood spots prepared from blood specimens submitted to a reference laboratory in Kenya. Dried blood spots did not perform well with the Kalon herpes simplex virus type 2 assay. Focus HerpeSelect 2 was 98.
View Article and Find Full Text PDFReasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study.
Int J Tuberc Lung Dis
February 2014
Epicentre, Paris, France.
Setting: Armenia, a country with a high prevalence of drug-resistant tuberculosis (DR-TB).
Objective: To identify factors related to default from DR-TB treatment in Yerevan.
Design: Using a retrospective cohort design, we compared defaulters with patients who were cured, completed or failed treatment.
Sensitivity and specificity of herpes simplex virus-2 serological assays among HIV-infected and uninfected urban Ugandans.
Int J STD AIDS
September 2010
Department of Global Health, University of Washington, Seattle, WA 98102, USA.
Herpes simplex virus type 2 (HSV-2) is a risk factor for HIV-1 infection. We characterized HSV-2 serology assay performance in HIV-positive and HIV-negative Africans. Serostatus for HSV-2 and HIV-1 was determined in 493 serum specimens stored from a community HSV-2 prevalence survey in Kampala, Uganda.
View Article and Find Full Text PDFBackground: Several commercial type-specific serologic tests are available for herpes simplex virus type 2 (HSV-2). Poor specificity of some tests has been reported on samples from sub-Saharan Africa.
Methods: To summarize the performance of the tests using samples from sub-Saharan Africa, we conducted a systematic review of publications reporting performance of commercially available HSV-2 tests against a gold standard (Western Blot or monoclonal antibody-blocking EIA).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!